T Cell Lymphoma Clinical Trial
Official title:
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma
This is a phase 1 clinical trial of autologous CD7-CAR T cells in the treatment of high-risk acute T-cell leukemia / lymphoma. Twenty subjects will be enrolled. Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | April 20, 2025 |
Est. primary completion date | April 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 70 Years |
Eligibility | Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Diagnosed as a high-risk acute T-cell leukemia / lymphoma patient with complete remission within 3 months and persistent positive of minimal residual disease, expressing tumor surface antigen CD7 2. Refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma patients with no blasts in peripheral blood by flow cytometry and suspending anti-neoplastic treatment for more than 2 weeks 3. Male or female, aged 0-70 years 4. No serious allergic constitution 5. Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score 0 to 2 6. Have life expectancy of at least 60 days based on investigator's judgement 7. CD7 positive in bone marrow or peripheral blood or immunohistochemistry 8. Candidates aged 8-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. And Pediatric patients under 8 years old could be recruited after signing an informed consent form by a legal surrogate (Guardian) 9. Minimal residual disease was positive after chemotherapy and there were contraindications of allogeneic hematopoietic stem cell transplantation. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Intracranial hypertension or disorder of consciousness 2. Symptomatic heart failure or severe arrhythmia 3. Symptoms of severe respiratory failure 4. Complicated with other types of malignant tumors 5. Diffuse intravascular coagulation 6. Serum creatinine and / or blood urea nitrogen = 1.5 times of the normal value 7. Suffering from septicemia or other uncontrollable infections 8. Patients with uncontrollable diabetes 9. Severe mental disorders 10. Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI) 11. Have received organ transplantation (excluding hematopoietic stem cell transplantation); 12. Reproductive-aged female patients with positive blood HCG test 13. Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis |
Country | Name | City | State |
---|---|---|---|
China | Beijing Boren Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Boren Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DLT rate | The DLT rate to the CAR-T treatment | 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06420076 -
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
|
Phase 1/Phase 2 | |
Completed |
NCT01561833 -
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
|
Phase 1 | |
Withdrawn |
NCT04334174 -
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
|
Phase 2 | |
Recruiting |
NCT05367856 -
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT00798096 -
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
|
Phase 2 | |
Completed |
NCT03770000 -
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05996185 -
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT01430013 -
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04502446 -
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
|
Phase 1 | |
Terminated |
NCT04973527 -
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
|
Phase 1 | |
Recruiting |
NCT05230680 -
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03672084 -
Allo-HSCT as First-line Consolidation in High-risk PTCL
|
||
Recruiting |
NCT05852028 -
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
|
||
Enrolling by invitation |
NCT03628612 -
Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified
|
Phase 2 | |
Recruiting |
NCT00974324 -
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00877656 -
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05772728 -
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
|
N/A | |
Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 | |
Terminated |
NCT00880867 -
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
|
Phase 1 |